What is Sangamo Therapeutics Inc. (SGMO) Stock Return on Shareholders’ Capital?

Sangamo Therapeutics Inc. (NASDAQ: SGMO) stock fell -0.63% on Friday to $4.77 against a previous-day closing price of $4.80. With 2.14 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.79 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.8100 whereas the lowest price it dropped to was $4.6200. The 52-week range on SGMO shows that it touched its highest point at $11.49 and its lowest point at $3.12 during that stretch. It currently has a 1-year price target of $14.49. Beta for the stock currently stands at 1.43.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SGMO was up-trending over the past week, with a rise of 7.19%, but this was up by 3.92% over a month. Three-month performance surged to 4.15% while six-month performance fell -16.17%. The stock lost -49.58% in the past year, while it has lost -36.40% so far this year. A look at the trailing 12-month EPS for SGMO yields -1.21 with Next year EPS estimates of -1.44. For the next quarter, that number is -0.35. This implies an EPS growth rate of -37.00% for this year and 0.00% for next year.

Float and Shares Shorts:

At present, 146.22 million SGMO shares are outstanding with a float of 121.88 million shares on hand for trading. On Jul 14, 2022, short shares totaled 10.32 million, which was 7.03% higher than short shares on Jun 14, 2022. In addition to Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D. as the firm’s CEO, Pres & Director, Ms. Prathyusha Duraibabu CPA, M.B.A. serves as its Sr. VP, CFO & Principal Accounting Officer.

Institutional Ownership:

Through their ownership of 55.72% of SGMO’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 35.28% of SGMO, in contrast to 21.69% held by mutual funds. Shares owned by individuals account for 20.70%. As the largest shareholder in SGMO with 7.21% of the stake, Wasatch Advisors, Inc. holds 10,576,997 shares worth 10,576,997. A second-largest stockholder of SGMO, The Vanguard Group, Inc., holds 9,830,153 shares, controlling over 6.70% of the firm’s shares. BlackRock Fund Advisors is the third largest shareholder in SGMO, holding 8,894,841 shares or 6.06% stake. With a 3.54% stake in SGMO, the SPDR S&P Biotech ETF is the largest stakeholder. A total of 5,194,668 shares are owned by the mutual fund manager. The Wasatch Ultra Growth Fund, which owns about 2.92% of SGMO stock, is the second-largest Mutual Fund holder. It holds 4,280,057 shares valued at 17.72 million. CS Invt. Fds. 2 – holds 2.52% of the stake in SGMO, owning 3,700,000 shares worth 15.32 million.

An Overview of Recent Financials:

Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2022, SGMO reported revenue of $28.23M and operating income of -$45.26M. Over the past year, revenue came in at $112.65M while operating income stood at -$182.30M. It generated -$43.98M net income for the quarter, which came to -$176.33M over the last twelve months. The EBITDA in the recently reported quarter was -$40.32M and diluted EPS was -$0.30. EBITDA for the full year was -$163.62M.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SGMO since 11 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 3 believe that the stock is worth HOLDING, 1 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SGMO analysts setting a high price target of $25.00 and a low target of $4.40, the average target price over the next 12 months is $14.49. Based on these targets, SGMO could surge 424.11% to reach the target high and fall by -7.76% to reach the target low. Reaching the average price target will result in a growth of 203.77% from current levels.

EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. SGMO will report FY 2022 earnings on 03/02/2023. Analysts have provided yearly estimates in a range of -$1.19 being high and -$1.68 being low. For SGMO, this leads to a yearly average estimate of -$1.42. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Sangamo Therapeutics Inc. reported -$0.29 EPS against a consensus estimate of -$0.29. The surprise factor in the prior quarter was $0.01. Based on analyst estimates, the high estimate for the next quarter is -$0.32 and the low estimate is -$0.41. The average estimate for the next quarter is thus -$0.35.

Summary of Insider Activity:

Insiders traded SGMO stock several times over the past three months with 2 Buys and 2 Sells. In these transactions, 11,784 shares were bought while 12,367 shares were sold. The number of buy transactions has increased to 18 while that of sell transactions has risen to 24 over the past year. The total number of shares bought during that period was 624,784 while 369,786 shares were sold.

Leave a Comment

Your email address will not be published.